Loading…
Develops long-acting peptide therapies for endocrine and metabolic diseases including hypoparathyroidism and obesity.
Develops long-acting peptide therapies for endocrine and metabolic diseases including hypoparathyroidism and obesity.
Has no product to sell, so it is funded by money raised from investors, and any future income would come from selling its own drugs or licensing them to a larger drugmaker. Its platform engineers peptides to be dosed less often, such as once weekly. It listed in 2024.
Moat: none (IP / patents). Clinical-stage biotech with proprietary long-acting peptide chemistry but no approved products yet.
Headquarters: Carmel, Indiana, US · Founded: 2019 · Employees: 63
Size MBX Biosciences (MBX) is a United States Health Care company (Biotechnology) with a market value of $2.47B, the 1660th largest of 3,117 United States companies the cockpit tracks. Shares closed at $51.35 on 6 Nov 2026.
Performance Over six months the shares gained 25.4%, against -10.8% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.
Short interest Short interest is 9.2% of the free float (15 Oct 2026).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$303,000 | -$248,000 | -$244,000 | -$157,000 | -$56,000 |
| EBITDA | -$118M | -$97.8M | -$68.0M | -$35.2M | -$25.1M |
| Net income | -$104M | -$87.0M | -$61.9M | -$32.6M | -$26.1M |
| Free cash flow | -$85.2M | -$81.9M | -$55.6M | -$32.1M | -$23.6M |
| Capital expenditure | $2.53M | $1.93M | $874,000 | $129,000 | $441,000 |
| Total debt | $3.34M | $598,000 | $213,000 | $518,000 | $527,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| MBX Biosciences MBX | $2.47B | +25% | n/a | n/a | n/a | n/a |
| Ascendis Pharma A/S ASND | $16.0B | +8% | +128% | 10% | 12.8× | 36.4% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 4.0× | 0.1% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MBX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.6% | +1.3% | 8th lowest of 21 |
| 6-month return | +25.4% | -10.8% | 7th highest of 20 |
| Distance from 52-week high | -29.3% | -33.2% | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | 67.9× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | 17.1× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | 22.6× | n/a | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | 21.9× | n/a | n/a |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Walvax Biotechnology 300142.SZ | China | $2.71B | -12% | -23% | 5% | 10.3× | 31.3% | -3.8% |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.73B | -18% | +163% | -268% | 13.2× | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.76B | -23% | +18% | 27% | 4.7× | 0.5% | +36.0% |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Xeris Biopharma XERS | United States | $2.77B | +133% | +36% | 11% | 8.8× | 33.3% | +70.2% |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |